Search Results: "PARP inhibitor"

We’ve awarded our annual research prizes at the NCRI Conference in Glasgow. Find out who won our Future Leaders, Jane Wardle, and Lifetime Achievement prizes.

A drug could help slow the progression of some advanced ovarian cancers and extend the time that patients show no signs of disease, according to new research.

In this Science Surgery post we explore the work being done to use existing treatments in other types of cancer.

By combining radiotherapy with different kinds of drugs, scientists hope that both can be made more effective.

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma.

In this week’s cancer news there’s Brexit plans, viruses being used as treatments, and disagreements over screening for prostate cancer.

Unpublished trial results have found that a drug which targets genetic vulnerabilities in tumour cells can delay some advanced ovarian cancers from worsening.

Our scientists have been at the forefront of PARP inhibitor research and development. Here we share the story of rucaparib.

Read about some of the progress we’ve made over the last financial year and about some of the big themes from the year.

Scientists have developed a blood test that could help doctors select the best treatment for men with aggressive prostate cancer.